Core Viewpoint - Duori Pharmaceutical is forecasting a significant net loss for the year 2025, with expected losses ranging from 76.25 million to 99.12 million yuan for net profit attributable to shareholders, and from 82.25 million to 106.92 million yuan for net profit after deducting non-recurring gains and losses [1] Group 1: Financial Performance - The company's main product, sodium acetate Ringer's injection, is expected to see a substantial decline in sales volume and price due to winning the bid for the 10th batch of national centralized drug procurement at the end of 2024, which will take effect from April 2025, leading to a significant drop in revenue and gross profit for 2025 [1] - The subsidiary Sichuan Duori completed its acquisition in November 2024 and will be included in the consolidated financial statements, with steady business progress expected in 2025, resulting in revenue growth; however, this growth will not cover R&D and financial expenses, leading to continued losses for the period [1]
多瑞医药：预计2025年全年净亏损7624.49万元—9911.83万元